CHRM2

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.

Major depressive disorder

MDD

A common psychiatric disorder. It is a complex trait characterized by one or more major depressive episodes without a history of manic, mixed, or hypomanic episodes. A major depressive episode is characterized by at least 2 weeks during which there is a new onset or clear worsening of either depressed mood or loss of interest or pleasure in nearly all activities. Four additional symptoms must also be present including changes in appetite, weight, sleep, and psychomotor activity; decreased energy; feelings of worthlessness or guilt; difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation, plans, or attempts. The episode must be accompanied by distress or impairment in social, occupational, or other important areas of functioning.

None

Disease susceptibility is associated with variants affecting the gene represented in this entry.

Phosphorylated in response to agonist treatment.

Belongs to the G-protein coupled receptor 1 family. Muscarinic acetylcholine receptor subfamily. CHRM2 sub-subfamily.

• Cell membrane
• Multi-pass membrane protein
• Postsynaptic cell membrane
• Multi-pass membrane protein
• Phosphorylation in response to agonist binding promotes receptor internalization.

Muscarinic acetylcholine receptor M2, CHRM2

• entrezGene:1129
• omim:118493
• swissprot:P08172

Proteins

Neuroscience

51715Da